Search
Atomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational[A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … [L6037] However, these stimulant medications are limited by dose-related side effects and concerns of abuse.
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Hydroxycitronellal
go.drugbank.com/drugs/DB14187ApprovedHydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain … Sensitivity to hydroxycitronellal may be identified with a clinical patch test.
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate … [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533]
Tyrothricin
go.drugbank.com/drugs/DB13503ApprovedWithdrawnMoreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years … Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity [L4019, L4021, L4022], although certain formulations that are safe for human use like throat lozenges do
Mixtures: Emercreme No4 Ont EfaLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigational[L45206] This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial. … Zylonta also received approval in the EU on December 22, 2022.
Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linkerMethylcellulose
go.drugbank.com/drugs/DB11228ApprovedInvestigationalMethyl cellulose is a hydrophilic white powder in pure form and dissolves in cold (but not in hot) water, forming a clear viscous solution or gel. … Like cellulose, it is not digestible, not toxic, and not allergenic
Chloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approved[L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054] … [A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].
Synonyms: N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamineCategories: Analgesics, Non-NarcoticPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalgrowth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801ApprovedPariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … continued approval potentially contingent on confirmatory trials.